The CARTBCMA-HCB-01 study in Spain evaluated the safety and efficacy of ARI0002h CAR T-cell therapy, targeting BCMA, in relapsed or refractory multiple myeloma patients. The study enrolled 35 patients and assessed the overall response rate after 100 days and the occurrence of cytokine-release syndrome or neurotoxic events within the first 30 days. Results showed deep and sustained responses with low toxicity, particularly in terms of neurological events. The study’s findings highlight the potential of ARI0002h CAR T-cell therapy as an effective treatment option for relapsed or refractory multiple myeloma patients. Further research and development of point-of-care manufacturing may increase the availability of this therapy worldwide.

To know more: About the original article click here.